title: Risk factors for damaged liver function after chemotherapy in hepatitis B virus carriers with non-Hodgkin lymphoma.
abstract: The goal of this study was to investigate damaged liver function after chemotherapy in hepatitis B virus (HBV) carriers with non-Hodgkin lymphoma (NHL) and to evaluate risk factors associated with a high risk of damaged liver function. Clinical histories of 134 HBV carriers with NHL who were treated with chemotherapy were obtained and analyzed for the occurrence of damaged liver function and other related high-risk factors. Analysis showed that 76 patients (56.7%) had damaged liver function after chemotherapy: 6 patients (7.9%) had I degree, 17 patients (22.4%) had II degree, 20 patients (26.3%) had III degree, and 33 patients (43.4%) had IV degree damage. After treatment, 18 patients (23.7%) continued to receive chemotherapy according to their original schedule, 39 patients (51.3%) delayed chemotherapy, 16 patients (21.1%) stopped chemotherapy, and 3 patients (3.9%) died. Analysis of a binary multivariate logistic regression model showed that administration of steroids was a high-risk factor for damaged liver function after chemotherapy in NHL patients. The incidence of damaged liver function after chemotherapy is high among HBV carriers with NHL; therefore, administration of steroid chemotherapy is a high-risk factor.
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: X
authors: X
authors: Li
authors: Department of International Radiology, Affliliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: X W
authors: XW
authors: Fan
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: W
authors: W
authors: Liu
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: L
authors: L
authors: Guo
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: Y
authors: Y
authors: Li
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: X
authors: X
authors: Hu
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: X
authors: X
authors: Liang
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
authors: X P
authors: XP
authors: Ma
authors: Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China shuneyang@yeah.net.
authors: S E
authors: SE
authors: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology / Q000821:virology; D002648:Child; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000503:physiopathology* / Q000821:virology; D006515:Hepatitis B virus / Q000502:physiology; D054884:Host-Pathogen Interactions; D006801:Humans; D008099:Liver / Q000473:pathology / Q000503:physiopathology* / Q000821:virology; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D055815:Young Adult